MediXall Group files Form 12b-25 for late periodic reports

Q: What did MediXall Group (MDXL) file with the SEC?

MediXall filed a Form 12b-25 notification dated May 15, 2026. The filing states certain required periodic reports could not be completed without "unreasonable effort or expense," and lists multiple delinquent 10-K and 10-Q filings the company is preparing to submit.

Q: Which periodic reports is MDXL delinquent in filing?

The company reports delinquency in the 2024 Form 10-K, the Form 10-Qs for quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, and the 2025 Form 10-K. The notice states these reports are being prepared for filing with the SEC.

Q: Who is the contact for the filing and how can they be reached?

The contact listed is Travis Jackson, Chief Financial Officer. The telephone number provided in the notification is 800-381-1787. This contact is named for inquiries regarding the late-filing notification.

MediXall Group, Inc. submitted a Form 12b-25 notification dated May 15, 2026 reporting a late filing for the period ended March 31, 2026.

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

NT 10-Q

Rhea-AI Filing Summary

MediXall Group, Inc. submitted a Form 12b-25 notification dated May 15, 2026 reporting a late filing for the period ended March 31, 2026. The company cites that "certain financial and other information" could not be provided without "unreasonable effort or expense." The filing states the company is delinquent in its 2024 Form 10-K, the Form 10-Qs for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, and the 2025 Form 10-K, and that it is preparing those reports for submission.

Key Figures

Form type: Form 12b-25 Period ended: March 31, 2026 Notification date: May 15, 2026 +2 more

5 metrics

Form type Form 12b-25 Notification of late filing

Period ended March 31, 2026 Period referenced on the Form 12b-25 cover

Notification date May 15, 2026 Date the notification was signed by CFO Travis Jackson

Delinquent filings listed 2024 Form 10-K; 2025 Form 10-K; three 10-Qs Specifically: Qs ended March 31, June 30, and Sept 30, 2025

Contact phone 800-381-1787 Contact for notification: Travis Jackson, CFO

Key Terms

Rule 12b-25, Form 12b-25, Delinquent periodic reports

3 terms

Rule 12b-25 regulatory

""PART II 12b-25(b) and (c)" notification language"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 12b-25 regulatory

""NOTIFICATION OF LATE FILING" cover line"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

Delinquent periodic reports regulatory

""The Company is delinquent in filing the 2024 Form 10-K""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MediXall Group (MDXL) file with the SEC?

MediXall filed a Form 12b-25 notification dated May 15, 2026. The filing states certain required periodic reports could not be completed without "unreasonable effort or expense," and lists multiple delinquent 10-K and 10-Q filings the company is preparing to submit.

Which periodic reports is MDXL delinquent in filing?

The company reports delinquency in the 2024 Form 10-K, the Form 10-Qs for quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, and the 2025 Form 10-K. The notice states these reports are being prepared for filing with the SEC.

Does the 12b-25 state whether reported earnings will change materially?

The notice answers that no significant change in results of operations is anticipated; the company checked "No" to anticipated significant changes versus the prior year. No quantitative earnings estimates or details are provided in the excerpt.

Who is the contact for the filing and how can they be reached?

The contact listed is Travis Jackson, Chief Financial Officer. The telephone number provided in the notification is 800-381-1787. This contact is named for inquiries regarding the late-filing notification.

What reason does MDXL give for the late filings?

The company states that "certain financial and other information necessary for an accurate and full completion of the Report could not be provided within the prescribed time period without unreasonable effort or expense." No further specifics are included in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/15/2026 - 06:43 AM EDT


	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549



	FORM 12b-25	SEC FILE NUMBER 333-194337
	NOTIFICATION OF LATE FILING	CUSIP NUMBER

(Check one):

Form 10-K

Form 20-F

Form 11-K

Form 10-Q

Form 10-D

Form N-CEN

Form N-CSR


For Period Ended:		March 31, 2026

	Transition Report on Form 10-K

	Transition Report on Form 20-F

	Transition Report on Form 11-K

	Transition Report on Form 10-Q

For the Transition Period Ended:

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

MediXall Group, Inc.

Full Name of Registrant

Former Name if Applicable

104 N 4th St.

Address of Principal Executive Office (Street and Number)

Leesburg, FL 34748

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)


	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
ü

	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

Certain financial and other information necessary for an accurate and full completion of the Report could not be provided within the prescribed time period without unreasonable effort or expense.

PART IV — OTHER INFORMATION


(1)	Name and telephone number of person to contact in regard to this notification

	Travis Jackson	800	381-1787
	(Name)	(Area Code)	(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes				No	ü
	The Company is delinquent in filing the 2024 Form 10-K, the Form 10-Q for the periods ended March 31, 2025, June 30, 2025 and September 30, 2025 and the 2025 Form 10-K. We are in the process of preparing the respective Form 10-K’s and Form 10-Q’s for filing with the Securities and Exchange Commission.

(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes				No	ü

	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.



	MediXall Group, Inc.
	(Name of Registrant as Specified in Charter)

	has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:		May 15, 2026	By:	/s/ Travis Jackson
				Travis Jackson, Chief Financial Officer

Source: View Original Filing on SEC EDGAR